Leishmaniases and chronic inflammatory diseases are the cause of millions of deaths in the world each year. The treatment of leishmaniasis is facing serious drawbacks particularly due to the limited number of effective medicines, the resistance, and the toxicity of available drugs. On the other hand, many drugs are used for the management of inflammatory disorders. However, the most commonly prescribed although efficient is highly toxic with multiples side effects. New leads compounds for the development of new anti-leishmanial and anti-inflammatory drugs are needed. Over the past decade, several studies on the potential of endophytes to produce bioactive metabolites have been reported. We are presenting in the present review the status of research from 2000 to 2019 on the anti-leishmanial and anti-inflammatory metabolites isolated from endophytes from diverse habitats. An emphasis was put on existing gaps in the literature to inspire and guide future investigations. We hope that this review will help accelerate the drug discovery against leishmaniases and inflammation-associated disorders.

Graphic Abstract

中文翻译：

---

内生菌的抗利什曼原虫和抗炎剂：综述。


利什曼病和慢性炎症性疾病每年导致世界数百万人死亡。利什曼病的治疗面临着严重的缺陷，特别是由于有效药物的数量有限、现有药物的耐药性和毒性。另一方面，许多药物用于治疗炎症性疾病。然而，最常用的药物虽然有效，但毒性很大，具有多种副作用。需要新的先导化合物来开发新的抗利什曼病和抗炎药物。在过去的十年中，已经报道了几项关于内生菌产生生物活性代谢物的潜力的研究。我们在本综述中介绍了 2000 年至 2019 年从不同栖息地的内生菌中分离出的抗利什曼原虫和抗炎代谢物的研究状况。重点放在文献中现有的空白上，以启发和指导未来的研究。我们希望这次审查将有助于加速针对利什曼病和炎症相关疾病的药物发现。

 图文摘要